# Oncolytics Biotech Inc: overview ONCY · Nasdaq · CIK 1129928 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/oncy.md) · [Financials](/companies/oncy/financials.md) · [Filings](/companies/oncy/filings.md) · [Insiders](/companies/oncy/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.06)](/filings/0001129928-26-000033.md) | [(0.06)](/filings/0001129928-26-000051.md) | [(0.08)](/filings/0001129928-26-000033.md) | [(0.08)](/filings/0001129928-26-000051.md) | | Free cash flow | $k | [(4,734)](/filings/0001129928-26-000033.md) | [(4,106) d](/filings/0001129928-26-000051.md) | [(7,299)](/filings/0001129928-26-000033.md) | [(8,138) d](/filings/0001129928-26-000051.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.49)](/filings/0001129928-24-000018.md) | [(0.43)](/filings/0001129928-25-000019.md) | [(0.41)](/filings/0001129928-25-000019.md) | [(0.30)](/filings/0001129928-26-000020.md) | [(0.30)](/filings/0001129928-26-000020.md) | | Free cash flow | $m | not reported | not reported | not reported | [(20.1)](/filings/0001129928-26-000020.md) | [(20.1)](/filings/0001129928-26-000020.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: ifrs-full:ProfitLossFromOperatingActivities; Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: ifrs-full:ProfitLoss; Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: ifrs-full:DilutedEarningsLossPerShare; Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Capital expenditure: ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities; Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/oncy/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [MARSHALL WACE, LLP](/funds/1318757.md) | 2026-06-30 | $708.1k | 745,350 | | Reduced −114,481 | | [XTX Topco Ltd](/funds/1828301.md) | 2026-06-30 | $247.8k | 260,903 | | New +260,903 | | [SEEDS INVESTOR LLC](/funds/2021047.md) | 2026-06-30 | $245.4k | 258,306 | | New +258,306 | | [INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC](/funds/1818604.md) | 2026-06-30 | $181.3k | 201,260 | | New +201,260 | | [Connective Capital Management, LLC](/funds/1543568.md) | 2026-06-30 | $176.4k | 185,712 | | New +185,712 | | [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $161.4k | 169,898 | | New +169,898 | | [TOCQUEVILLE ASSET MANAGEMENT L.P.](/funds/883961.md) | 2026-06-30 | $139.6k | 147,000 | | New +147,000 | | [Everhart Financial Group, Inc.](/funds/1852858.md) | 2026-06-30 | $133.8k | 140,899 | | New +140,899 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $127.4k | 134,129 | | New +134,129 | | [PFG Investments, LLC](/funds/1973224.md) | 2026-06-30 | $121.9k | 128,300 | | New +128,300 | ## Recent filings [All 920 filings](/companies/oncy/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-27 | 09:46 ET | [8-K](/filings/0001129928-26-000076.md) | 8.01 Other events | 0001129928-26-000076 | | 2026-10-20 | 09:37 ET | [8-K](/filings/0001129928-26-000074.md) | 8.01 Other events | 0001129928-26-000074 | | 2026-10-14 | 09:33 ET | [8-K](/filings/0001129928-26-000072.md) | 8.01 Other events | 0001129928-26-000072 | | 2026-10-13 | 08:10 ET | [8-K](/filings/0001129928-26-000070.md) | 8.01 Other events | 0001129928-26-000070 | | 2026-10-06 | 16:27 ET | [DEF 14A](/filings/0001129928-26-000066.md) | Proxy statement, period 2025-12-31 | 0001129928-26-000066 | | 2026-09-29 | 09:34 ET | [8-K](/filings/0001129928-26-000059.md) | 8.01 Other events | 0001129928-26-000059 | | 2026-09-28 | 09:32 ET | [8-K](/filings/0001129928-26-000057.md) | 8.01 Other events | 0001129928-26-000057 | | 2026-09-10 | 08:17 ET | [8-K](/filings/0001129928-26-000055.md) | 8.01 Other events | 0001129928-26-000055 | | 2026-08-18 | 09:03 ET | [8-K](/filings/0001129928-26-000053.md) | 8.01 Other events | 0001129928-26-000053 | | 2026-08-12 | 16:18 ET | [10-Q](/filings/0001129928-26-000051.md) | Quarterly report, period 2026-06-30 | 0001129928-26-000051 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001129928-26-000020.md), filed Mar 30, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1129928 - Tickers: ONCY - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: NV - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 09:47 ET. No prices; not investment advice.